The GLP-1 Tipping Point: How Skyrocketing Costs Exposed PBM Influence and How Employers Can Take Back Control

GLP-1 medications have been a tipping point in exposing the role that PBM’s have over controlling prescription drug access and cost. Not all PBM’s are created equal and most drive what is easiest and most profitable for the PBM.  It’s critical that employers play an active role in controlling their health plan strategy to support improved health outcomes and health plan investments. Tune into this episode of The Pulse as we uncover the role of the PBM in prescription drug access and costs and what employers need to do to redefine expectations and outcomes from PBMs.

Panelists will discuss:

• How a drug is approved by the FDA and if that clinically is providing the most effective approach to leverage medications.
• PBM prior authorization strategies and what appropriate expectations should be
• Why and how PBMs and Manufacturers leverage rebates to force formulary restrictions
• The opportunity for plan savings related to generic medications that are not leveraged by PBMs
• What strategies related to GLP-1 appear to be most successful in driving improved health outcomes and an ROI on health plan investments

This episode includes guest speakers:

Ge Bai, PhD, CPA.
Professor at Johns Hopkins Carey Business School and Professor of Health Management at Johns Hopkins Bloomberg School of Public Health

Dr. Jonathan Bonnet, MD, MPH, CAQSM, FAAFP, FACLM, DipABOM, DipACLM.
Associate Professor at Stanford University School of Medicine and Program Director of Medical Weight Loss at the Clinical Resource Hub Weight Management Center at the Palo Alto Veteran’s Affairs

Jennifer Perlitch RPh., MBA.
Assistant Vice President – Pharmacy at AECRx